Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 32303623.
- Also identified by DOI 10.1136/thoraxjnl-2019-214195 and PMC identifier 7361016.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alpha-1 antitrypsin deficiency (AATD) is a cause of bronchiectasis. Guidelines for bronchiectasis from the British Thoracic Society do not recommend to routinely test patients for AATD. In contrast, guidelines for AATD recommend routine screening. This contradiction, in part, results from the lack of data from large studies performing comprehensive screening. We screened 1600 patients with bronchiectasis at two centres in the UK from 2012 to 2016. In total, only eight individuals with AATD were identified representing 0.5% of the overall population. We conclude that routine screening for AATD in bronchiectasis in the UK has a low rate of detection. Further studies are required in different geographical regions, which may have a higher prevalence of AATD.
Medical subject headings
- Bronchiectasis
- Mass Screening
- Practice Guidelines as Topic
- alpha 1-Antitrypsin Deficiency